These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26315299)

  • 1. HMGN5 blockade by siRNA enhances apoptosis, suppresses invasion and increases chemosensitivity to temozolomide in meningiomas.
    He J; Liu C; Wang B; Li N; Zuo G; Gao D
    Int J Oncol; 2015 Oct; 47(4):1503-11. PubMed ID: 26315299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of cyclin D1 in meningioma is associated with malignancy grade and causes abnormalities in apoptosis, invasion and cell cycle progression.
    Cheng G; Zhang L; Lv W; Dong C; Wang Y; Zhang J
    Med Oncol; 2015 Jan; 32(1):439. PubMed ID: 25502086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of HMGN5 suppresses the viability and invasion of human urothelial bladder cancer 5637 cells in vitro and in vivo.
    Gan Y; Tan J; Yang J; Zhou Y; Dai Y; He L; Yao K; Tang Y
    Med Oncol; 2015 Apr; 32(4):136. PubMed ID: 25796505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing HMGN5 suppresses cell growth and promotes chemosensitivity in esophageal squamous cell carcinoma.
    Liu X; Ma W; Yan Y; Wu S
    J Biochem Mol Toxicol; 2017 Dec; 31(12):. PubMed ID: 28914995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of CDC2 expression inhibits proliferation, enhances apoptosis, and increases chemosensitivity to temozolomide in glioblastoma cells.
    Zhou B; Bu G; Zhou Y; Zhao Y; Li W; Li M
    Med Oncol; 2015 Jan; 32(1):378. PubMed ID: 25433945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of RLIP76 Required for Proliferation in Meningioma Is Associated with Recurrence.
    Fan SY; Jiang JD; Qian J; Lu YC; Hu GH; Luo C; Hou WD; Wang Q
    PLoS One; 2015; 10(5):e0125661. PubMed ID: 25993541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The high-mobility group nucleosome-binding domain 5 is highly expressed in breast cancer and promotes the proliferation and invasion of breast cancer cells.
    Weng M; Song F; Chen J; Wu J; Qin J; Jin T; Xu J
    Tumour Biol; 2015 Feb; 36(2):959-66. PubMed ID: 25315189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of oncogenic HMGN5 increases the sensitivity of prostate cancer cells to gemcitabine.
    Guo Z; Zhang X; Li X; Xie F; Su B; Zhang M; Zhou L
    Oncol Rep; 2015 Mar; 33(3):1519-25. PubMed ID: 25572120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMGN5 knockdown sensitizes prostate cancer cells to ionizing radiation.
    Su B; Shi B; Tang Y; Guo Z; Yu X; He X; Li X; Gao X; Zhou L
    Prostate; 2015 Jan; 75(1):33-44. PubMed ID: 25307178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. microRNA-340 Suppresses Tumorigenic Potential of Prostate Cancer Cells by Targeting High-Mobility Group Nucleosome-Binding Domain 5.
    Wei P; Qiao B; Li Q; Han X; Zhang H; Huo Q; Sun J
    DNA Cell Biol; 2016 Jan; 35(1):33-43. PubMed ID: 26394192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMGN5 Silencing Suppresses Cell Biological Progression via AKT/MAPK Pathway in Human Glioblastoma Cells.
    Ma Q; Wang X; Wang H; Song W; Wang Q; Wang J
    Biomed Res Int; 2020; 2020():8610271. PubMed ID: 32596388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HMGN5 promotes invasion and migration of colorectal cancer through activating FGF/FGFR pathway.
    Zhu GJ; Liu F; Xu YG; Zhao CX; Zhao JG; Sun C
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1330-1338. PubMed ID: 33629303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. microRNA-183-3p Inhibits Progression of Human Prostate Cancer by Downregulating High-Mobility Group Nucleosome Binding Domain 5.
    Li Y; He S; Zhan Y; He A; Gong Y; Ji G; Huang C; Peng D; Guan B; Li X; Zhou L
    DNA Cell Biol; 2019 Aug; 38(8):840-848. PubMed ID: 31314587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
    Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
    Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression and clinical significance of high mobility group nucleosome binding domain 5 in human osteosarcoma.
    Zhou X; Yuan B; Yuan W; Wang C; Gao R; Wang J
    Tumour Biol; 2014 Jul; 35(7):6539-47. PubMed ID: 24687550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small interfering RNA targeting HMGN5 induces apoptosis via modulation of a mitochondrial pathway and Bcl-2 family proteins in prostate cancer cells.
    Zhang XY; Guo ZQ; Ji SQ; Zhang M; Jiang N; Li XS; Zhou LQ
    Asian J Androl; 2012 May; 14(3):487-92. PubMed ID: 22504871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMGN5: a potential oncogene in gliomas.
    Qu J; Yan R; Chen J; Xu T; Zhou J; Wang M; Chen C; Yan Y; Lu Y
    J Neurooncol; 2011 Sep; 104(3):729-36. PubMed ID: 21373965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-224 targets ERG2 and contributes to malignant progressions of meningioma.
    Wang M; Deng X; Ying Q; Jin T; Li M; Liang C
    Biochem Biophys Res Commun; 2015 May; 460(2):354-61. PubMed ID: 25783051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-mobility group nucleosome-binding domain 5 increases drug resistance in osteosarcoma through upregulating autophagy.
    Yang C; Gao R; Wang J; Yuan W; Wang C; Zhou X
    Tumour Biol; 2014 Jul; 35(7):6357-63. PubMed ID: 24664583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo.
    Kargiotis O; Chetty C; Gogineni V; Gondi CS; Pulukuri SM; Kyritsis AP; Gujrati M; Klopfenstein JD; Dinh DH; Rao JS
    Int J Oncol; 2008 Nov; 33(5):937-47. PubMed ID: 18949356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.